CLPT

SEC source: 0001193125-26-002922 · ownership.xml · nonDerivative · entry 1

FLETCHER R JOHN · CIK 0001215024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,662

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2025.

SEC source: 0001193125-26-002980 · ownership.xml · nonDerivative · entry 1

STIGALL L. JEREMY · CIK 0001929859 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,356

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0001193125-26-002973 · ownership.xml · nonDerivative · entry 1

SABRA MAZIN · CIK 0001947604 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,470

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0001193125-26-002959 · ownership.xml · nonDerivative · entry 1

D'Alessandro Danilo · CIK 0001825163 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,330

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0001193125-26-002949 · ownership.xml · nonDerivative · entry 1

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,565

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0001193125-25-297322 · ownership.xml · derivative · entry 2

D'Alessandro Danilo · CIK 0001825163 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,082

Underlying: Common Stock · 3,555 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Mr. D'Alessandro paid the exercise price for the option in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.

F2 · derivative.exercise_date: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is March 6, 2023.

SEC source: 0001193125-25-297322 · ownership.xml · nonDerivative · entry 1

D'Alessandro Danilo · CIK 0001825163 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Mr. D'Alessandro paid the exercise price for the option in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.

SEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 4

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 217,059

F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

SEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 3

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 217,359

F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $28.08 to $29.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

SEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 2

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 219,340

F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $27.08 to $28.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

SEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 1

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 225,939

F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $26.07 to $27.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

SEC source: 0001193125-25-239059 · ownership.xml · nonDerivative · entry 1

SABRA MAZIN · CIK 0001947604 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,084

F1 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001193125-25-228835 · ownership.xml · nonDerivative · entry 1

FLETCHER R JOHN · CIK 0001215024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,240

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

SEC source: 0001193125-25-228831 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,949

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

SEC source: 0001193125-25-228824 · ownership.xml · nonDerivative · entry 1

Richards Timothy T. · CIK 0001601831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,870

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

SEC source: 0000950170-25-093154 · ownership.xml · nonDerivative · entry 1

Richards Timothy T. · CIK 0001601831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,315

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025.

SEC source: 0000950170-25-093132 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,634

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025.

SEC source: 0000950170-25-093109 · ownership.xml · nonDerivative · entry 1

FLETCHER R JOHN · CIK 0001215024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,975

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025.

SEC source: 0000950170-25-093183 · ownership.xml · nonDerivative · entry 1

STIGALL L. JEREMY · CIK 0001929859 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,355

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0000950170-25-093198 · ownership.xml · nonDerivative · entry 1

D'Alessandro Danilo · CIK 0001825163 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,368

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0000950170-25-093170 · ownership.xml · nonDerivative · entry 1

SABRA MAZIN · CIK 0001947604 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,564

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0000950170-25-093159 · ownership.xml · nonDerivative · entry 1

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,311

F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

SEC source: 0000950170-25-085702 · ownership.xml · nonDerivative · entry 1

STIGALL L. JEREMY · CIK 0001929859 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,747

F1 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0000950170-25-085714 · ownership.xml · nonDerivative · entry 1

Richards Timothy T. · CIK 0001601831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,381

F1 · kind: This sale of shares was made to cover the tax liability incident to the vesting of 21,903 shares on May 16, 2025 under a restricted stock unit granted to the director on May 16, 2024.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $13.27 to $13.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000950170-25-085700 · ownership.xml · nonDerivative · entry 1

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,887

F1 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0000950170-25-085709 · ownership.xml · nonDerivative · entry 1

D'Alessandro Danilo · CIK 0001825163 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,992

F1 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0000950170-25-085074 · ownership.xml · nonDerivative · entry 1

BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 243,522

F1 · kind: This sale of shares is incident to the net share settlement of 21,247 shares which vested on March 6, 2025 under a restricted stock unit granted to the reporting person on March 6, 2023.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $13.20 to $13.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

SEC source: 0000950170-25-082344 · ownership.xml · nonDerivative · entry 2

FALLON LYNNETTE C · CIK 0001195654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,901

F1 · kind: This sale of shares was made to cover the tax liability incident to the vesting of 21,903 shares on May 16, 2025 under a restricted stock unit granted to the director on May 16, 2024.

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $12.84 to $12.92. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000950170-25-082344 · ownership.xml · nonDerivative · entry 1

FALLON LYNNETTE C · CIK 0001195654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,101

F1 · kind: This sale of shares was made to cover the tax liability incident to the vesting of 21,903 shares on May 16, 2025 under a restricted stock unit granted to the director on May 16, 2024.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.84 to $12.81. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000950170-25-077172 · ownership.xml · derivative · entry 1

Klein Matthew B. · CIK 0001808968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-077203 · ownership.xml · derivative · entry 1

FALLON LYNNETTE C · CIK 0001195654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-077201 · ownership.xml · derivative · entry 1

FLETCHER R JOHN · CIK 0001215024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-077190 · ownership.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-077186 · ownership.xml · derivative · entry 1

JOHNSON B KRISTINE · CIK 0001231984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-077162 · ownership.xml · derivative · entry 1

LIAU LINDA M. · CIK 0001890712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-077157 · ownership.xml · derivative · entry 1

Richards Timothy T. · CIK 0001601831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-074448 · ownership.xml · derivative · entry 2

Klein Matthew B. · CIK 0001808968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074448 · ownership.xml · nonDerivative · entry 1

Klein Matthew B. · CIK 0001808968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074543 · ownership.xml · derivative · entry 2

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074543 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074519 · ownership.xml · derivative · entry 2

FLETCHER R JOHN · CIK 0001215024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074519 · ownership.xml · nonDerivative · entry 1

FLETCHER R JOHN · CIK 0001215024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074466 · ownership.xml · derivative · entry 2

JOHNSON B KRISTINE · CIK 0001231984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074466 · ownership.xml · nonDerivative · entry 1

JOHNSON B KRISTINE · CIK 0001231984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,699

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074501 · ownership.xml · derivative · entry 2

FALLON LYNNETTE C · CIK 0001195654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074501 · ownership.xml · nonDerivative · entry 1

FALLON LYNNETTE C · CIK 0001195654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074436 · ownership.xml · derivative · entry 2

LIAU LINDA M. · CIK 0001890712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074436 · ownership.xml · nonDerivative · entry 1

LIAU LINDA M. · CIK 0001890712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074420 · ownership.xml · derivative · entry 2

Richards Timothy T. · CIK 0001601831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-074420 · ownership.xml · nonDerivative · entry 1

Richards Timothy T. · CIK 0001601831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.